title: [Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer].
abstract: The dynamics of hormonal levels and tumor markers after the first administration of long-acting luteinizing hormone-releasing hormone (LH-RH) analogue were evaluated in patients with prostate cancer. Eight patients with histopathologically proved prostate cancer who were previously untreated were studied. The surge in plasma testosterone was recognized in 7 patients after the first administration of a long-acting LH-RH analogue, and reached the highest level after the 3rd day in 6 patients and 14th day in 1 patient. The onset of flare-up reaction due to a transient increase in plasma testosterone was recognized in 3 patients, whose clinical symptoms and signs were increased bone pain in 2 patients and acute urinary retention in 1 patient. An abnormal level of serum prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) was observed in 7 of the 8 patients before treatment. The serum PAP and PSA levels slightly increased after treatment in 4 and 3 patients, respectively. These findings suggest that the combination of estrogen or antiandrogen would allow a safer use of long-acting LH-RH analogue to prevent the risk of a flare-up reaction associated with the first administration of long-acting LH-RH analogue.
authors.affiliation: Department of Urology, Saitama Medical School.
authors.forename: S
authors.initials: S
authors.lastname: Takeuchi
authors.forename: K
authors.initials: K
authors.lastname: Yoshida
authors.forename: A
authors.initials: A
authors.lastname: Tosaka
authors.forename: N
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Uchijima
authors.forename: H
authors.initials: H
authors.lastname: Saitoh
mesh_terms: D000135:Acid Phosphatase / Q000097:blood*; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D003692:Delayed-Action Preparations; D006062:Gonadotropins / Q000097:blood; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy; D013739:Testosterone / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D003692:Delayed-Action Preparations; D006062:Gonadotropins; D017273:Goserelin; D013739:Testosterone; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen